Meanwhile, RSBDP was demonstrated to inhibit 2,4,6-trinitrobenzene sulfonic acid (TNBS)–induced colitis in rats by downregulating IL-1, IL-6, TNF-α, and IFN-γ; upregulating colonic mucosal occludin, claudin-5, and ZO-1 mRNA protein expression; and promoting the repair of tight junction protein colonic epithelium (Xiong et al., 2021). The gene discussed is TNF; the disease is colitis.